Search the Newsreel

Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know

Gilead Sciences (GILD) closed the most recent trading day at $129.31, moving -1.18% from the previous trading session. The stock fell short of the S&P 500, which registered a gain of 0.05% for the day. Elsewhere, the Dow gained 0.46%, while the tech-heavy Nasdaq …

J&J, Gilead among recipients of EU drug nods this week (JNJ)

The European Medicines Agency's expert panel endorsed 12 new medicines and eight label expansions this week, impacting major pharmaceutical companies. Johnson & Johnson and Gilead are among the U.S. drugmakers receiving positive recommendations for their products. These approvals could allow J&J to enter the …

GILD|Gilead Sciences Inc|Kurs:138.360|Änderung %:+0.220

EU panel recommends Trodelvy-Keytruda after 35% lower progression-or-death risk

Gilead Sciences announced that the European Medicines Agency's CHMP has recommended marketing authorization for Trodelvy in combination with Keytruda for first-line treatment of PD-L1-positive metastatic triple-negative breast cancer. This recommendation is based on the ASCENT-04/KEYNOTE-D19 study, which showed a 35% reduced risk of disease …

CHMP Recommends Gilead’s Trodelvy® Plus Keytruda® in PD-(L)1-Positive First-Line Metastatic Triple-Negative Breast Cancer

– A Second Approval in First-Line Would Establish Trodelvy as a Backbone Therapy Across PD-L1 Status in the European Union – – ASCENT-04/KEYNOTE-D19 Demonstrated a Highly Statistically Significant and Clinically Meaningful Reduction in the Risk of Disease Progression or Death – FOSTER CITY, Calif., …

Can Gilead's Efforts to Develop New Treatments Solidify HIV Franchise?

Gilead Sciences, Inc. GILD has a market-leading HIV franchise, led by flagship HIV therapies — Biktarvy for treatment and Descovy for prevention. The company's HIV business continues to maintain momentum, driven by solid performances of Biktarvy and Descovy, and incremental contributions from Yeztugo. Biktarvy …

Canadian Large Cap Leaders Split Corp. Declares Distribution

TORONTO, July 23, 2026 (GLOBE NEWSWIRE) -- (TSX: NPS) – Canadian Large Cap Leaders Split Corp. (the “Company”) announces distribution payable on August 14, 2026, to Class A Shareholders of record at the close of business on July 31, 2026. Share Class Ticker Amount …

Société à capital scindé leaders canadiens à grande capitalisation déclare une distribution

TORONTO, 23 juill. 2026 (GLOBE NEWSWIRE) -- (TSX: NPS) – Société à capital scindé leaders canadiens à grande capitalisation (la « Société ») annonce une distribution payable le 14 août 2026 aux détenteurs d’actions de catégorie A inscrits à la fermeture des bureaux le …

AIDS 2026: Gilead, governments must make HIV prevention medicine more accessible

Doctors Without Borders (MSF) urged Gilead Sciences and governments to make the HIV prevention medicine lenacapavir more accessible in low- and middle-income countries, especially Brazil. Lenacapavir is an injectable pre-exposure prophylaxis (PrEP) that is nearly 100-percent effective against HIV but is currently priced out …

Canadian Large Cap Leaders Split Corp. Announces Class A Share Split

How Gilead Is Working With Cultural Influencers to Bring Attention to HIV Stigma and Elevate HIV Prevention

Gilead Sciences is engaging cultural influencers and artists to combat HIV stigma and increase awareness, as scientific advancements in treating and preventing HIV are not being matched by public understanding. Despite progress turning HIV into a manageable chronic condition, knowledge about the virus is …

Gilead (GILD) Stock Could Still Trade At A Discount Following Its 127% Run

Gilead Sciences (GILD) has seen a significant 126.8% return over the past five years, yet its stock remains undervalued according to various metrics and valuation models. Despite its strong performance, particularly in its HIV portfolio, and a P/E ratio close to the biotech industry …

[AIDS 2026] [Press release] Gilead & Merck: Investigational once-weekly oral HIV treatment regimen of islatravir and lenacapavir maintained virological suppression in adults with HIV who switched antiretroviral therapy

Gilead Sciences and Merck will present detailed outcomes from their Phase 3 ISLEND-1 and ISLEND-2 trials at AIDS 2026. The investigational once-weekly oral HIV treatment regimen of islatravir 2 mg/lenacapavir 300 mg (ISL/LEN) demonstrated effectiveness in virally suppressed adults with HIV who switched from …

Press Release: Gilead Sciences to Release Second Quarter 2026 Financial Results on Tuesday, August 4, 2026

Gilead Sciences announced its plans to release second-quarter 2026 financial results on Tuesday, August 4, 2026. The company will host a webcast and conference call to discuss these results later that day. Interested parties can access the webcast and accompanying slides on the company's …

ETFs Investing in Gilead Sciences, Inc. Stocks

This article lists various ETFs that include Gilead Sciences, Inc. (GILD0) stocks in their portfolios. The ETFs are sorted by market value and provide details such as weight, issuer, management style, expense ratio, assets under management (AUM), price, change percentage, and 3-year NAV total …

Gilead Sciences to Release Second Quarter 2026 Financial Results on Tuesday, August 4, 2026

FOSTER CITY, Calif., July 21, 2026--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2026 financial results and guidance will be released on Tuesday, August 4, 2026 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead's management will …

Gilead and Merck report weekly HIV trial results

Gilead Sciences (NASDAQ:GILD) and Merck (NYSE:MRK) have announced successful 48-week results for their once-weekly oral HIV regimen in two Phase 3 trials, ISLEND-1 and ISLEND-2. The trials showed that the treatment maintained viral suppression with a low percentage of patients above the viral-load threshold, …

Debt to equity ratio of Gilead Sciences, Inc. – BCS:GILD0

This article focuses on the debt to equity ratio of Gilead Sciences, Inc. (BCS:GILD0). While the information primarily consists of navigation and boilerplate text from a financial platform, it highlights the availability of financial data for the company on the Santiago Stock Exchange via …

Gilead, Merck Advance Potential Blockbuster Weekly HIV Pill

Gilead Sciences and Merck & Co. have announced positive Phase 3 trial results for their investigational once-weekly oral HIV regimen, ISL/LEN. The treatment demonstrated non-inferior efficacy to daily antiretroviral therapy and showed high patient satisfaction due to reduced treatment burden. These findings are expected …

Preferred dividends of Gilead Sciences, Inc. – BCS:GILDCL1

This page provides information on the preferred dividends of Gilead Sciences, Inc. under the ticker BCS:GILDCL1 on the Santiago Stock Exchange. It indicates that the market was closed with no trades recorded regarding these dividends.

Nasdaq 100 Movers: TRI, SNDK

In early trading on Tuesday, shares of SanDisk topped the list of the day's best performing components of the Nasdaq 100 index, trading up 9.7%. Year to date, SanDisk registers a 542.7% gain. And the worst performing Nasdaq 100 component thus far on the …

Gilead, Merck’s phase 3 data back first weekly HIV pill

New phase 3 data from two Islend clinical trials indicate that the experimental once-weekly, single-tablet combination of Gilead’s lenacapavir and Merck’s islatravir (ISL/LEN) effectively maintains HIV viral suppression, matching daily treatments like Gilead’s Biktarvy. If approved, ISL/LEN would be the first complete weekly oral …

Gilead to Present New HIV Research at AIDS 2026 Across Prevention, Treatment and Cure

– Long-Term Data from the PURPOSE 1 and PURPOSE 2 Trials Demonstrate Continued High Efficacy, High Adherence and Consistent Safety Profile of Twice-Yearly Lenacapavir for PrEP – – Detailed Phase 3 Results from the ISLEND-1 and ISLEND-2 Trials Highlight the Potential of Weekly HIV …

Press Release: Gilead Sciences Completes Acquisition of Tubulis Further Strengthening Oncology Portfolio

Gilead Sciences has announced the completion of its strategic acquisition of Tubulis, a German-based biotechnology company. This acquisition is set to enhance Gilead's oncology portfolio, particularly in the area of antibody-drug conjugates (ADCs) for cancer treatment. The integration of Tubulis's innovative ADC platform and …

Gilead Sciences' Quarterly Earnings Preview: What You Need to Know

Gilead sign is seen during the fifth China International Import Expo By Eagle Gilead Sciences, Inc. (GILD), headquartered in Foster City, California, is a biopharmaceutical company that discovers, develops, and commercializes medicines in the areas of unmet medical need. Valued at $166.7 billion by …

Lobbying Update: $1,590,000 of GILEAD SCIENCES INC lobbying was just disclosed

A recent Lobbying Disclosure Act filing for Q2 2026 reveals that GILEAD SCIENCES INC lobbied with $1,590,000 on issues including pharmaceuticals, intellectual property, drug pricing, and tax policy. The article also provides GILD stock trading activity by members of Congress and company insiders, as …

Here's How Much $100 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today

Gilead Sciences (NASDAQ: GILD) has outperformed the market over the last 20 years with an average annual return of 11.43%. An initial investment of $100 in GILD twenty years ago would now be worth $854.46 due to compounded returns. The article highlights the significant …

Gilead Stock Tops 3 GARP Picks Trading On More Measured Valuations

This article highlights three Growth at a Reasonable Price (GARP) stocks—Belden (BDC), Daktronics (DAKT), and Gilead Sciences (GILD)—that offer solid fundamentals and appear reasonably valued compared to the current AI-driven market trends. It discusses their revenue streams, market caps, and potential risks, suggesting they …

Gilead Sciences (GILD) Sees a More Significant Dip Than Broader Market: Some Facts to Know

In the latest close session, Gilead Sciences (GILD) was down 1.48% at $134.28. This change lagged the S&P 500's daily loss of 1.01%. Meanwhile, the Dow lost 0.77%, and the Nasdaq, a tech-heavy index, lost 1.4%. Shares of the HIV and hepatitis C drugmaker …

With Up To Date campaign, Gilead brings HIV prevention into the dating conversation

Gilead Sciences has launched its "Up To Date" campaign, featuring comedians Nicole Byer and Devon Walker, to normalize conversations around HIV prevention, testing, and PrEP, particularly targeting Black women. The campaign uses humor and culturally relevant media placements like streaming services, social media, and …

Is Gilead Sciences (GILD) Fully Valued Following Mixed Earnings And A Full Year EPS Miss?

Gilead Sciences (GILD) reported mixed Q2 earnings with revenue up 4.4% to $6.96 billion but missed full-year EPS estimates. While one valuation narrative suggests Gilead is 6.2% overvalued at $136.30 with a fair value of $128.38, another Discounted Cash Flow (DCF) model indicates it …

Gilead Sciences (GILD) CFO sells 3,000 shares in pre-set 10b5-1 plan

Gilead Sciences' Chief Financial Officer, Andrew D. Dickinson, sold 3,000 shares of common stock on July 15, 2026, for approximately $390,000, under a pre-arranged Rule 10b5-1 trading plan. After this transaction, Dickinson still directly holds 168,646 shares. The sale was executed at an average …

Gilead Sciences Inc (GILD) Stock Up 3.5% but GF Value Says Overvalued -- GF Score: 69/100

Gilead Sciences Inc (GILD) saw its stock price rise by 3.5% on July 16, 2026, reaching $136.30. Despite this gain, GuruFocus's GF Value™ estimates the stock to be significantly overvalued at $96.17, implying a 41.7% premium. The GF Score™ of 69/100 suggests above-average performance …

Gilead Sciences (NASDAQ: GILD) exec trades 3,000 shares under 10b5-1 plan

Johanna Mercier, Chief Comm & Corp Aff Officer of Gilead Sciences (NASDAQ: GILD), reported an open-market sale of 3,000 shares of common stock on July 15, 2026, at an average price of $129.9192 per share. This sale was conducted under a Rule 10b5-1 trading …

Gilead Sciences chief comm & corp aff officer sells $389,757 in stock

Johanna Mercier, Chief Communications & Corporate Affairs Officer at Gilead Sciences (NASDAQ:GILD), sold 3,000 shares of company stock for approximately $389,757 on July 15, 2026, as part of a pre-arranged trading plan. Despite the sale, the stock is considered potentially undervalued according to InvestingPro …

Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know

Gilead Sciences (GILD) has garnered investor attention, with its stock performing well recently. The article discusses factors influencing its future performance, including revisions to earnings estimates, projected revenue growth, past financial results, and valuation metrics. Zacks currently rates Gilead as a Zacks Rank #3 …